Familial hypercholesterolemia (FH) is caused by loss-of-function mutations in the LDL receptor (LDLR). In FH, statins have reduced efficacy compared to normal individuals because:
- A Statins are rapidly metabolized by upregulated CYP3A4 in FH patients
- B FH patients have PCSK9 gain-of-function mutations that directly neutralize statins
- C Statins require functional LDL receptors to mediate their LDL-lowering effect — fewer receptors limits the response ✓
- D Statins are ineffective because FH patients overproduce apoB-100 independently of LDL receptor
Explanation
Statins inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis. This upregulates LDLR expression on hepatocytes, which then clear more LDL from circulation. In homozygous FH (LDLR absent or severely dysfunctional), statins upregulate an already non-functional receptor — the LDL clearance mechanism is severely impaired regardless of statin dose. Thus statins show markedly reduced efficacy in homozygous FH (LDL may fall only 10–20%). These patients require LDL apheresis, PCSK9 inhibitors, or lomitapide/mipomersen. In heterozygous FH (one functional allele), statins are more effective as they upregulate the remaining normal LDLR allele.
Reference: Harper's Illustrated Biochemistry, 32nd ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.